Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Integrating disease progression models, non-clinical pharmacokinetic data and treatment response endpoints to optimize intravitreal dosing regimens.

Basile AS, Johnson TR, Klamerus KJ, Zhou D, Sultan MB, Amantea M, Nickens DJ.

Int J Clin Pharmacol Ther. 2014 Jul;52(7):574-86. doi: 10.5414/CP201998.

PMID:
24755127
2.

[Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].

Lommatzsch A, Heimes B, Gutfleisch M, Spital G, Dietzel M, Pauleikhoff D.

Ophthalmologe. 2011 Mar;108(3):244-51. doi: 10.1007/s00347-010-2221-9. German.

PMID:
20571805
3.

Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion.

Ramezani A, Esfandiari H, Entezari M, Moradian S, Soheilian M, Dehsarvi B, Yaseri M.

Graefes Arch Clin Exp Ophthalmol. 2012 Aug;250(8):1149-60. doi: 10.1007/s00417-012-1941-8. Epub 2012 Feb 14.

PMID:
22331147
4.

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial.

Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, Soheilian M, Keshavarzi G, Mohebbi MR.

Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):483-9. Epub 2007 Oct 5.

PMID:
17917738
5.

Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration.

Inoue M, Kadonosono K, Arakawa A, Yamane S, Ishibashi T.

Jpn J Ophthalmol. 2015 May;59(3):173-8. doi: 10.1007/s10384-015-0374-4. Epub 2015 Mar 4.

PMID:
25733493
6.

Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.

Ding X, Li J, Hu X, Yu S, Pan J, Tang S.

Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.

PMID:
21293319
7.

Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review.

Mahmood S, Kumar N, Lenfestey PM, Murjaneh S, Heimann H, Harding SP.

Eye (Lond). 2009 Mar;23(3):530-5. doi: 10.1038/eye.2008.101. Epub 2008 Apr 18.

PMID:
18425070
8.

Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.

Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR; TREX-AMD Study Group.

Ophthalmology. 2015 Dec;122(12):2514-22. doi: 10.1016/j.ophtha.2015.08.009. Epub 2015 Sep 29.

9.

Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.

Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Heimann H, Meyer CH; Retinal Vein Occlusion Study Group.

Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):183-92. doi: 10.1007/s00417-010-1470-2. Epub 2010 Aug 18.

10.

Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study.

El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF.

Am J Ophthalmol. 2012 Mar;153(3):481-489.e1. doi: 10.1016/j.ajo.2011.08.018. Epub 2011 Oct 19.

PMID:
22014603
11.

Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.

Cho HJ, Lee TG, Han SY, Kim HS, Kim JH, Han JI, Lew YJ, Kim JW.

Graefes Arch Clin Exp Ophthalmol. 2016 Jan;254(1):23-30. doi: 10.1007/s00417-015-2993-3. Epub 2015 Apr 1.

PMID:
25825231
12.

Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).

Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF.

Retina. 2012 Mar;32(3):434-57. doi: 10.1097/IAE.0B013E31822C290F.

PMID:
22374154
13.

Treatment of choroidal neovascularization using intravitreal bevacizumab.

Pedersen R, Soliman W, Lund-Andersen H, Larsen M.

Acta Ophthalmol Scand. 2007 Aug;85(5):526-33. Epub 2007 May 18.

14.

FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.

Ng DS, Kwok AK, Tong JM, Chan CW, Li WW.

Retina. 2015 Dec;35(12):2457-68. doi: 10.1097/IAE.0000000000000610.

PMID:
26035400
15.

Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion.

Ramezani A, Esfandiari H, Entezari M, Moradian S, Soheilian M, Dehsarvi B, Yaseri M.

Acta Ophthalmol. 2014 Nov;92(7):e530-9. doi: 10.1111/aos.12317. Epub 2013 Dec 26.

16.

Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.

Ahmadieh H, Taei R, Riazi-Esfahani M, Piri N, Homayouni M, Daftarian N, Yaseri M.

Retina. 2011 Oct;31(9):1819-26. doi: 10.1097/IAE.0b013e31820d58f2.

PMID:
21555967
17.
18.

Intravitreal pegaptanib sodium (MacugenĀ®) for treatment of diabetic macular oedema: a morphologic and functional study.

Rinaldi M, Chiosi F, dell'Omo R, Romano MR, Parmeggiani F, Semeraro F, Mastropasqua R, Costagliola C.

Br J Clin Pharmacol. 2012 Dec;74(6):940-6. doi: 10.1111/j.1365-2125.2012.04291.x.

19.

Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.

Forte R, Cennamo G, Finelli M, Cesarano I, D'Amico G, De Crecchio G, Cennamo G.

Acta Ophthalmol. 2010 Dec;88(8):e305-10. doi: 10.1111/j.1755-3768.2010.02021.x. Epub 2010 Oct 14.

20.

Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment.

Bloch SB, la Cour M, Sander B, Hansen LK, Fuchs J, Lund-Andersen H, Larsen M.

Acta Ophthalmol. 2013 Feb;91(1):42-7. doi: 10.1111/j.1755-3768.2011.02268.x. Epub 2011 Oct 19.

Supplemental Content

Support Center